Novavax/$NVAX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Ticker
$NVAX
Sector
Primary listing
Employees
952
Headquarters
Website
Novavax Metrics
BasicAdvanced
$1.1B
3.18
$2.07
2.30
-
Price and volume
Market cap
$1.1B
Beta
2.3
52-week high
$11.55
52-week low
$5.01
Average daily volume
3.9M
Financial strength
Current ratio
2.267
Quick ratio
1.854
Long term debt to equity
-157.082
Total debt to equity
-160.297
Interest coverage (TTM)
17.62%
Profitability
EBITDA (TTM)
463.228
Gross margin (TTM)
59.42%
Net profit margin (TTM)
32.10%
Operating margin (TTM)
40.22%
Effective tax rate (TTM)
2.55%
Revenue per employee (TTM)
$1,120,000
Management effectiveness
Return on assets (TTM)
18.01%
Return on equity (TTM)
-100.06%
Valuation
Price to earnings (TTM)
3.178
Price to revenue (TTM)
0.998
Price to book
-6.82
Price to tangible book (TTM)
-3.96
Price to free cash flow (TTM)
-2.761
Free cash flow yield (TTM)
-36.22%
Free cash flow per share (TTM)
-2.383
Growth
Revenue change (TTM)
20.27%
Earnings per share change (TTM)
-204.01%
3-year revenue growth (CAGR)
-16.77%
10-year revenue growth (CAGR)
39.88%
3-year earnings per share growth (CAGR)
-50.56%
10-year earnings per share growth (CAGR)
-13.29%
What the Analysts think about Novavax
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Novavax Financial Performance
Revenues and expenses
Novavax Earnings Performance
Company profitability
Novavax News
AllArticlesVideos
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
Investopedia·2 weeks ago
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Market Watch·2 weeks ago
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
Barrons·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novavax stock?
Novavax (NVAX) has a market cap of $1.1B as of December 16, 2025.
What is the P/E ratio for Novavax stock?
The price to earnings (P/E) ratio for Novavax (NVAX) stock is 3.18 as of December 16, 2025.
Does Novavax stock pay dividends?
No, Novavax (NVAX) stock does not pay dividends to its shareholders as of December 16, 2025.
When is the next Novavax dividend payment date?
Novavax (NVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Novavax?
Novavax (NVAX) has a beta rating of 2.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.